NO985066L - Terapeutisk behandling for VEGF-relaterte sykdommer - Google Patents

Terapeutisk behandling for VEGF-relaterte sykdommer

Info

Publication number
NO985066L
NO985066L NO985066A NO985066A NO985066L NO 985066 L NO985066 L NO 985066L NO 985066 A NO985066 A NO 985066A NO 985066 A NO985066 A NO 985066A NO 985066 L NO985066 L NO 985066L
Authority
NO
Norway
Prior art keywords
vegf
therapeutic treatment
related diseases
stimulated
neoplasia
Prior art date
Application number
NO985066A
Other languages
English (en)
Other versions
NO985066D0 (no
Inventor
Lloyd P Aiello
Michael R Jirousek
George L King
Louis Vignati
Douglas Kirk Ways
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO985066D0 publication Critical patent/NO985066D0/no
Publication of NO985066L publication Critical patent/NO985066L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Fremgangsmåte for inhibering av VEGF-stimulert endotelcellevekst, slik som forbundet med neoplasi, og VEGF- stimulert kapillarpermeabilitet, slik som forbundet med pulmonalt ødem, er beskrevet, særlig under anvendelse av p-isozymet som er selektivt for PKC- inhibitoren (S)-3,4-[N,N'-l,l'-((2' '- etoksy)-3'''(O)-4r''-(N,N-dimetyl- amino)-butan)-bis-(3,3'-indolyl)]-l(H)- pyrrol-2,5-dionhydrokloridsalt.
NO985066A 1996-05-01 1998-10-30 Terapeutisk behandling for VEGF-relaterte sykdommer NO985066L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1665896P 1996-05-01 1996-05-01
US84163597A 1997-04-30 1997-04-30
PCT/US1997/007752 WO1997040830A1 (en) 1996-05-01 1997-05-01 Therapeutic treatment for vegf related diseases

Publications (2)

Publication Number Publication Date
NO985066D0 NO985066D0 (no) 1998-10-30
NO985066L true NO985066L (no) 1998-12-21

Family

ID=26688913

Family Applications (1)

Application Number Title Priority Date Filing Date
NO985066A NO985066L (no) 1996-05-01 1998-10-30 Terapeutisk behandling for VEGF-relaterte sykdommer

Country Status (15)

Country Link
US (1) US6284751B1 (no)
EP (1) EP0915698A4 (no)
JP (1) JP2002504086A (no)
KR (1) KR20000065171A (no)
CN (1) CN1233177A (no)
AU (1) AU736333B2 (no)
BR (1) BR9710706A (no)
CA (1) CA2253608A1 (no)
CZ (1) CZ350098A3 (no)
EA (1) EA001779B1 (no)
IL (1) IL126837A0 (no)
NO (1) NO985066L (no)
NZ (1) NZ332645A (no)
PL (1) PL329851A1 (no)
WO (1) WO1997040830A1 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093740A (en) * 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
US6103712A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for asthma
US6103713A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for autoimmune diseases
US6979441B2 (en) * 1998-09-16 2005-12-27 Wilson T Crandall Method for topical treatment of carpal tunnel syndrome
US6306383B1 (en) * 1998-09-16 2001-10-23 Wilson T Crandall Method for topical treatment of scars with protein kinase C inhibitors
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
IL151045A0 (en) 2000-02-07 2003-04-10 Abbott Gmbh & Co Kg 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
AU2001296558A1 (en) 2000-10-03 2002-04-15 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
US6875165B2 (en) 2001-02-22 2005-04-05 Retinalabs, Inc. Method of radiation delivery to the eye
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
CN102813923B (zh) 2003-08-27 2015-04-01 奥普索特克公司 用于治疗眼新血管疾病的组合治疗
CN101005873B (zh) * 2004-02-12 2010-07-21 内奥维斯塔公司 用于眼内近程治疗的设备
EP1734996B1 (en) 2004-04-02 2013-05-22 The Regents of The University of California Methods and compositions for treating and preventing disease associated with alpha v beta 5 integrin
EP1740591B1 (en) 2004-04-02 2009-06-17 OSI Pharmaceuticals, Inc. 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
US7795205B2 (en) * 2004-04-12 2010-09-14 Canyon Pharmaceuticals, Inc. Methods for effecting regression of tumor mass and size in a metastasized pancreatic tumor
TW200613306A (en) 2004-07-20 2006-05-01 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
AU2006313724B2 (en) * 2005-11-14 2010-12-23 Universitat Zurich Staurosporine derivatives for use in alveolar rhabdomyosarcoma
JP2009515655A (ja) 2005-11-15 2009-04-16 ネオビスタ、インコーポレイテッド 眼内近接照射療法のための方法および装置
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
AU2014201660B2 (en) * 2007-10-19 2015-09-03 Centre Hospitalier Universitaire De Bordeaux Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
US8987262B2 (en) 2007-10-19 2015-03-24 Universite de Bordeaux Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
EP2050441A1 (en) 2007-10-19 2009-04-22 Université Victor Segalen Bordeaux 2 Use of beta blocker for the manufacture of a medicament for the treatment of hemangiomas
AU2009256236A1 (en) 2008-06-04 2009-12-10 Neovista, Inc. Handheld radiation delivery system for advancing a radiation source wire
EP2758079A4 (en) * 2011-09-21 2015-05-13 Univ North Carolina PROCESS WITH BIOMARKERS FOR LIVER DISEASE

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ227850A (en) 1988-02-10 1991-11-26 Hoffmann La Roche Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders
EP0699204B1 (en) * 1993-05-28 1998-04-15 Cephalon, Inc. Use of indolocarbazole derivatives to treat a pathological condition of the prostate
UA44690C2 (uk) * 1993-12-07 2002-03-15 Елі Ліллі Енд Компані Макроциклічна сполука іміду біс-індол-малеїнової кислоти, спосіб її одержання та фармацевтична композиція, макроциклічні сполуки іміду біс-індол-малеїнової кислоти та біс-індол-малеїнового ангідриду, спосіб одержання (варіанти)
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
JPH07238044A (ja) 1993-12-07 1995-09-12 Eli Lilly & Co ビスインドリルマレイミドの改良合成法
US5545636A (en) 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
US5491242A (en) 1994-06-22 1996-02-13 Eli Lilly And Company Protein kinase C inhibitors
US5481003A (en) 1994-06-22 1996-01-02 Eli Lilly And Company Protein kinase C inhibitors

Also Published As

Publication number Publication date
EA001779B1 (ru) 2001-08-27
CA2253608A1 (en) 1997-11-06
NZ332645A (en) 2000-07-28
AU736333B2 (en) 2001-07-26
US6284751B1 (en) 2001-09-04
PL329851A1 (en) 1999-04-12
EP0915698A4 (en) 1999-08-11
KR20000065171A (ko) 2000-11-06
JP2002504086A (ja) 2002-02-05
BR9710706A (pt) 1999-08-17
WO1997040830A1 (en) 1997-11-06
NO985066D0 (no) 1998-10-30
EA199800969A1 (ru) 1999-06-24
EP0915698A1 (en) 1999-05-19
CZ350098A3 (cs) 1999-11-17
CN1233177A (zh) 1999-10-27
AU2935597A (en) 1997-11-19
IL126837A0 (en) 1999-09-22

Similar Documents

Publication Publication Date Title
NO985066L (no) Terapeutisk behandling for VEGF-relaterte sykdommer
CA2253613A1 (en) Therapeutic treatment for vegf related occular diseases
NZ332563A (en) Use of protein kinase c inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
IS1995B (is) Tríazól afleiður, gagnlegar í meðhöndlun
NO991100D0 (no) Assosiasjon av NO syntaseinhibitorer med feller for reaktive oksygenformer
NO20075066L (no) Farmasoytisk sammensetning som inneholder isoflavoner
IS6467A (is) Díhýdró-1,3,5-tríasín amínafleiður og notkun þeirra í meðferð
NO20006460L (no) 4, 5, 6 og 7-Indol og indolinderivater, deres fremstilling og anvendelse
NO985808D0 (no) Terapeutisk behandling for kardiovaskulµre sykdommer
EE9800333A (et) Uued furaandiarüülmetülideeni derivaadid, nende valmistamise meetod ja kasutamine teraapias
NZ334609A (en) Use of inhibitors of the beta isozyme of protein kinase C for treatment of sexual dysfunctions in mammals
NO990949L (no) Anvendelse av PKC-inhibitorer til fremstilling av et medikament for behandling av AIDS
NO970185L (no) Anvendelse av (S)-adenosyl-L-metionin (SAMe) og dets fysiologisk kompatible salter for behandling av reperfusjonsskade utlöst av temporær-fokal-ischemi
NO20021429L (no) 1,4-dioksacykloalkan-2-oner og 1,4-dioksacykloalken-2-oner
NO990948L (no) Anvendelse av PKC-inhibitorer til fremstilling av et medikament for behandling av HTLV-1-infeksjoner
DE50211461D1 (de) Pharmazeutische zusammensetzung enthaltend bulbophyllum
NO990947L (no) Anvendelse av inhibitorer for PKC til fremstilling av et medikament for behandling av sentralnervesystemsykdommer forbundet med HIV-infeksjon
ITMI971712A3 (it) Montatura perfezionata per occhiali in particolare montatura per occhiali comprendenti mezzi per la diffusione localizzata del suono
ITMI970547U1 (it) Montatura perfezionata per occhiali in particolare montatura per occhiali comprendenti mezzi per la diffusione localizzata del suono
IT245964Y1 (it) Dispositivo per l'ottimizzazione della penetrazione del calore neglistrati profondi sottocutanei, particolarmente nei trattamenti
IT247616Y1 (it) Bocchino monouso perfezionato, in particolare per narghile'.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application